The GLP-1 Data API
Continuously-updated database of GLP-1 medication safety, efficacy, pricing, patents, supply, and demand. 2,197+ data points across 15 side effects, 9 drugs, 11 countries. Built for researchers, pharma intelligence teams, and journalists — and already being read by the AI agents people ask about GLP-1 medications.
What you get
Side-effect database
2,197+ data points covering 15 side effects across 9 GLP-1 medications. Two-track methodology (clinical-trial vs real-world reports). Continuously updated from PubMed, FDA FAERS, ClinicalTrials.gov, and Google News coverage of regulatory actions worldwide (incl. CDSCO India, ANVISA Brazil, EMA/MHRA/WHO). Patient-community collection (Reddit) has been blocked since 2026-05-28 — see /en/data for live per-source status.
Economics data
Country-by-country pricing (list, typical-paid, generic vs branded). Patent timelines per jurisdiction. Manufacturing capacity (Novo Nordisk, Eli Lilly capex by site). Demand-driver trial readouts. Updated weekly via cloud agent + daily news pipeline.
Supply-demand forecast
Magistra's structured forecast through 2030 with bull/base/bear scenarios, manufacturing investments by site, generic capacity by country, and policy-lever analysis. Available as a citable JSON dataset.
India generics brand tracker
Brand-level tracking of India's post-patent semaglutide market: manufacturer, formulation, monthly INR price bands, DCGI status, and a per-row source-verification level. The current version is free to download as CSV or JSON; continuous dated updates, price-move history, and the batch/recall alert layer are what subscriptions fund. See the tracker.
Patient-journey predictor
Programmatic access to the side-effect risk model (log-odds with random-effects CIs), weight-trajectory predictor, muscle-loss risk score, and discontinuation outlook. Suitable for embedding in clinical or research applications.
GLP-1 Real-World Evidence Brief — August 2026
A PDF brief plus the full dataset CSV — a dated corpus snapshot, currently 2026-09-02 with 1,513 rows, each carrying its source, date, drug, and extraction confidence. 150 of those rows are April-2026 seed points, flagged in a "provenance" column and excluded from every published rate. Covers 15 side effects across 9 drugs, drawn from PubMed, FDA FAERS, ClinicalTrials.gov, news coverage of EMA/MHRA/WHO safety actions, and public community reports, plus the full methodology annex. The CSV is a point-in-time snapshot, not a live feed; the free API stays current.
What this is not: incidence rates. Only a minority of sources state a numeric rate, so our per-effect estimates rest on small samples — as of 14 September 2026 no effect rests on a single rate-bearing source any more (hair loss did until that morning and still rests on only two), one (emotional blunting) has no citable corpus rate at all and publishes no clinical number, and two (gallstones, pancreatitis) rest wholly or mostly on registry SERIOUS adverse-event rates, which are a floor on all-cause incidence and are labelled as such on every row (rateKind) — these memberships are recomputed daily, so read them from the API rather than from this sentence — and every estimate is published with its source count and a confidence grade, not as prevalence. The clinical and community tracks are kept separate and never blended; community reports carry self-selection bias. Treat the dataset as a sourced corpus and a discordance signal, not as an epidemiological estimate.
Known defect in this snapshot: until 10 September 2026, our ClinicalTrials.gov registry collector kept only the five highest-percentage arm rows per trial — a selection on the very figure it measures. 19 of 25 trials with stored registry rows are affected (the six pinned pivotal trials — SURMOUNT-1, SELECT, STEP 1, STEP 2, SURPASS-CVOT, retatrutide phase 2 — are not); pooled clinical figures drawing on an affected trial read high by an amount not yet quantified per effect. This 2026-09-02 snapshot predates both the fix and the re-collection. Current status: /data, and every /api/data response carries a samplingNote field until it is resolved.
Look before you buy: download a 31-row sample — every 49th row of the exact file, unmodified, with the same 13 columns. It is a systematic slice rather than a curated one, so 7 of its 31 rows carry a numeric rate, close to the 316 of 1,513 in the full file.
Pricing
- Side-effect overview endpoint
- Per-effect detail endpoint
- Forecast JSON dataset
- No hard rate limit — be reasonable
- Everything in Free
- Bulk export of full dataset
- Each export is stamped with its extraction date. The live corpus is overwritten in place, so back-dating rests on our public repo history and stored CSV exports, which between them hold a corpus state for five dates in April 2026 and for every day since 12 August 2026 (nothing between 27 April and 11 August 2026), plus one immutable snapshot of the production corpus per calendar month since August 2026 (20 August and 1 September 2026 so far). A repo-history rebuild reflects the committed file, which can lag that day's production state by a few rows. A dated export is never rewritten to hide a later correction: rows we have since found to be wrong stay in the file that recorded them, and every dated deliverable ships with an errata sheet listing them and what the live data says now
- Email support, 1 business day SLA
- Citation-ready dataset attribution
- Everything in Researcher
- Custom queries / data slices
- Demographic slices where reported — sex on 231 of 2,197 points (221 of them community self-reports), age range on 185 (167 community); the remainder are the few trial and news rows that state a sex or age band
- Monthly written intelligence briefing
- Same-day support
- Priority on new endpoints
Annual prepay = 2 months free. Custom enterprise tier for pharma manufacturers and HTAs available — email saurabh@magistra.health.
Public endpoints (try them)
https://magistra.health/api/data?q=overviewTop-level summary: total data points, drugs tracked, sources
https://magistra.health/api/data?q=effectsList of all side effects with clinical and real-world rates
https://magistra.health/api/data?q=effect&id=nauseaDetailed view of a specific side effect including modifier ORs
https://magistra.health/api/data/reviewLive model health-check — calibration, bias signals, proposed changes
https://magistra.health/data/glp1-supply-demand-forecast.jsonStructured forecast dataset (schema.org Dataset, CC BY 4.0)
https://magistra.health/data/india-semaglutide-tracker.jsonIndia semaglutide brand tracker — prices, formulations, DCGI status, per-row sources (CC BY 4.0; CSV at the same path)
https://magistra.health/data/glp1-aggregate-rates.csvAggregate pooled-rates table — per-effect pooled clinical estimate, 95% CI, stated-rates count, distinct sources (CC BY 4.0, redistributable with attribution; dated snapshot, JSON at the same path)
Full database, methodology, and citation guidance: /data · /methodology · /economics. Which effects have enough independent sources to trust: evidence strength by effect · the corpus-derived rates themselves.
Who subscribes
Research labs and academics
Citable dataset for systematic reviews, meta-analyses, comparative-effectiveness research, integrated with the published Magistra methodology (magistra.health/en/methodology).
Pharma intelligence and consulting
Continuous signal on competitor pricing, generic-launch readiness, supply-demand trajectory. Monthly written briefings help you contextualise our forecast against your internal models.
Health journalists and analysts
Reliable, sourced data for stories on GLP-1 economics, generics, gray market, regulatory shifts. Citable URLs, machine-readable forecast dataset.